1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Female Sexual Dysfunction - Pipeline Review, H2 2016

Female Sexual Dysfunction - Pipeline Review, H2 2016

  • December 2016
  • -
  • Global Markets Direct
  • -
  • 83 pages

Female Sexual Dysfunction - Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Female Sexual Dysfunction – Pipeline Review, H2 2016, provides an overview of the Female Sexual Dysfunction (Women’s Health) pipeline landscape.

Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Female Sexual Dysfunction – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction (Women’s Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Sexual Dysfunction (Women’s Health) pipeline guide also reviews of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 6, 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Female Sexual Dysfunction (Women’s Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction (Women’s Health).
- The pipeline guide reviews pipeline therapeutics for Female Sexual Dysfunction (Women’s Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Female Sexual Dysfunction (Women’s Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Female Sexual Dysfunction (Women’s Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Female Sexual Dysfunction (Women’s Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Female Sexual Dysfunction (Women’s Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Female Sexual Dysfunction (Women’s Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Female Sexual Dysfunction - Pipeline Review, H2 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Female Sexual Dysfunction Overview 8
Therapeutics Development 9
Pipeline Products for Female Sexual Dysfunction - Overview 9
Pipeline Products for Female Sexual Dysfunction - Comparative Analysis 10
Female Sexual Dysfunction - Therapeutics under Development by Companies 11
Female Sexual Dysfunction - Therapeutics under Investigation by Universities/Institutes 12
Female Sexual Dysfunction - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Female Sexual Dysfunction - Products under Development by Companies 16
Female Sexual Dysfunction - Products under Investigation by Universities/Institutes 17
Female Sexual Dysfunction - Companies Involved in Therapeutics Development 18
Allergan Plc 18
Apricus Biosciences Inc 19
Emotional Brain BV 20
Fabre-Kramer Pharmaceuticals Inc 21
GlaxoSmithKline Plc 22
M et P Pharma AG 23
Palatin Technologies Inc 24
Re-Pharm Ltd 25
TherapeuticsMD Inc 26
Valeant Pharmaceuticals International Inc 27
Female Sexual Dysfunction - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
(sildenafil citrate + testosterone) - Drug Profile 38
Product Description 38
Mechanism Of Action 38
RandD Progress 38
AB-101 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
RandD Progress 40
alprostadil - Drug Profile 41
Product Description 41
Mechanism Of Action 41
RandD Progress 41
bremelanotide - Drug Profile 48
Product Description 48
Mechanism Of Action 48
RandD Progress 48
estradiol acetate - Drug Profile 53
Product Description 53
Mechanism Of Action 53
RandD Progress 53
FKW-00GA - Drug Profile 56
Product Description 56
Mechanism Of Action 56
RandD Progress 56
gepirone hydrochloride ER - Drug Profile 57
Product Description 57
Mechanism Of Action 57
RandD Progress 57
S1B-3006 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
RandD Progress 58
S1B-307 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
RandD Progress 59
SIP-104 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
RandD Progress 60
Small Molecule for Sexual Dysfunction - Drug Profile 61
Product Description 61
Mechanism Of Action 61
RandD Progress 61
Small Molecules to Agonize Dopamine D2 Receptor for Sexual Dysfunction - Drug Profile 62
Product Description 62
Mechanism Of Action 62
RandD Progress 62
SPT-201 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
RandD Progress 63
Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile 64
Product Description 64
Mechanism Of Action 64
RandD Progress 64
TBS-2 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
RandD Progress 65
WC-3011 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
RandD Progress 68
Female Sexual Dysfunction - Dormant Projects 70
Female Sexual Dysfunction - Discontinued Products 72
Female Sexual Dysfunction - Product Development Milestones 73
Featured News and Press Releases 73
Nov 01, 2016: Bremelanotide Meets Co-Primary Endpoints in Palatins Phase 3 Trials for Hypoactive Sexual Desire Disorder 73
Sep 23, 2016: Palatin Technologies Presents Bremelanotide Neurobiology and Treatment Efficacy Review at World Meeting on Sexual Medicine 74
Sep 22, 2016: TherapeuticsMD Announces Multiple Presentations Related to Yuvvexy (TX-004HR) at Two Upcoming Medical Conferences 74
Sep 19, 2016: TherapeuticsMD Announces FDA Acceptance of New Drug Application and Prescription Drug User Fee Act (PDUFA) Date for Yuvvexy (TX-004HR) 76
Aug 04, 2016: Palatin Technologies Announces Completion of All Patient Visits In Phase 3 Clinical Trials of Bremelanotide for Hypoactive Sexual Desire Disorder 76
Jul 07, 2016: TherapeuticsMD Announces New Drug Application Submission for Yuvvexy (TX-004HR) 77
Jun 30, 2016: Catalent Announces Agreement To Commercially Supply Palatin Technologies' New Bremelanotide Female Sexual Dysfunction Product In Pen Injectors 77
Jun 29, 2016: TherapeuticsMD Announces Filing Timeline for Yuvvexy (TX-004HR) New Drug Application 77
May 14, 2016: TherapeuticsMD Presents Poster at ACOG 2016 with Additional Secondary Endpoint Data from Phase 3 Rejoice Trial 78
Mar 02, 2016: TherapeuticsMD to Present Data from Phase 3 Rejoice Trial at Upcoming Investor and Medical Conferences 78
Feb 26, 2016: Palatin Technologies Presents Bremelanotide Alcohol Interaction Study at International Society for the Study of Womens Sexual Health Annual Meeting 79
Feb 18, 2016: TherapeuticsMD Announces Poster Presentations at International Society for the Study of Women's Sexual Health Annual Meeting 79
Feb 08, 2016: Palatin Technologies Strengthens Intellectual Property Surrounding Use of Bremelanotide for Female Sexual Dysfunction 80
Dec 10, 2015: Palatin Technologies Achieves Target Patient Enrollment in Pivotal Phase 3 Studies for Bremelanotide for Female Sexual Dysfunction 80
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 82
Disclaimer 83

List of Tables
Number of Products under Development for Female Sexual Dysfunction, H2 2016 9
Number of Products under Development for Female Sexual Dysfunction - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Female Sexual Dysfunction - Pipeline by Allergan Plc, H2 2016 18
Female Sexual Dysfunction - Pipeline by Apricus Biosciences Inc, H2 2016 19
Female Sexual Dysfunction - Pipeline by Emotional Brain BV, H2 2016 20
Female Sexual Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2016 21
Female Sexual Dysfunction - Pipeline by GlaxoSmithKline Plc, H2 2016 22
Female Sexual Dysfunction - Pipeline by M et P Pharma AG, H2 2016 23
Female Sexual Dysfunction - Pipeline by Palatin Technologies Inc, H2 2016 24
Female Sexual Dysfunction - Pipeline by Re-Pharm Ltd, H2 2016 25
Female Sexual Dysfunction - Pipeline by TherapeuticsMD Inc, H2 2016 26
Female Sexual Dysfunction - Pipeline by Valeant Pharmaceuticals International Inc, H2 2016 27
Assessment by Monotherapy Products, H2 2016 28
Assessment by Combination Products, H2 2016 29
Number of Products by Stage and Target, H2 2016 31
Number of Products by Stage and Mechanism of Action, H2 2016 33
Number of Products by Stage and Route of Administration, H2 2016 35
Number of Products by Stage and Molecule Type, H2 2016 37
Female Sexual Dysfunction - Dormant Projects, H2 2016 70
Female Sexual Dysfunction - Dormant Projects (Contd..1), H2 2016 71
Female Sexual Dysfunction - Discontinued Products, H2 2016 72

List of Figures
Number of Products under Development for Female Sexual Dysfunction, H2 2016 9
Number of Products under Development for Female Sexual Dysfunction - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Products, H2 2016 15
Assessment by Monotherapy Products, H2 2016 28
Number of Products by Top 10 Targets, H2 2016 30
Number of Products by Stage and Top 10 Targets, H2 2016 30
Number of Products by Top 10 Mechanism of Actions, H2 2016 32
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 32
Number of Products by Routes of Administration, H2 2016 34
Number of Products by Stage and Routes of Administration, H2 2016 34
Number of Products by Molecule Types, H2 2016 36
Number of Products by Stage and Molecule Types, H2 2016 36

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Vivus, Inc. - Strategy, SWOT and Corporate Finance Report

Vivus, Inc. - Strategy, SWOT and Corporate Finance Report

  • $ 175
  • Company report
  • December 2016
  • by MarketLine

Summary Vivus, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product ...

Diabetic Neuropathy - Pipeline Review, H2 2016

Diabetic Neuropathy - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • November 2016
  • by Global Markets Direct

Diabetic Neuropathy - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy – Pipeline Review, H2 2016, provides an ...

Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2016

Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2016

  • $ 1500
  • Company report
  • September 2016
  • by Global Markets Direct

Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2016’, provides an overview ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.